2018 American Transplant Congress » Concurrent Session: Kidney Chronic Antibody Mediated Rejection
Date: Monday, June 4, 2018
Time: 2:30pm-4:00pm
Location: Room 4B
Session Type: Concurrent Session
Meeting: 2018 American Transplant Congress
- 2:42pm-2:54pm
Tocilizumab Stabilizes Renal Function in Kidney Transplant Recipients with Chronic Active Antibody Mediated Rejection (CAAMR)
- 2:54pm-3:06pm
Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR)
- 3:06pm-3:18pm
Class II Anti-HLA IgG2 and IgG3 DSAs Predict Poorer Outcomes in Chronic Antibody Mediated Rejection of Renal Allografts
- 3:18pm-3:30pm
Antibody-Verified Eplet Mismatches as Determinants of Premature Kidney Transplant Loss
« View all sessions from the 2018 American Transplant Congress